Bonafide, the women’s healthcare company focused on introducing a more natural approach to managing menopause symptoms with first-of-its-kind, evidence-based, OTC medical products, has acquired a patented, enhanced formulation of S-adenosylmethionine (SAM-e), with triple the bioavailability of competitor products. This acquisition boosts Bonafide’s patent holdings to more than 50 issued and pending patents that it owns or exclusively licenses and exemplifies its strategy…
